RFK Jr. is the nominee to run the agency that contains the FDA.
Soon-Shiong has a company with business before the FDA.
This isn't that hard.
ir.immunitybio.com/news-release...
Soon-Shiong has a company with business before the FDA.
This isn't that hard.
ir.immunitybio.com/news-release...
January 31, 2025 at 10:03 PM
RFK Jr. is the nominee to run the agency that contains the FDA.
Soon-Shiong has a company with business before the FDA.
This isn't that hard.
ir.immunitybio.com/news-release...
Soon-Shiong has a company with business before the FDA.
This isn't that hard.
ir.immunitybio.com/news-release...
ImmunityBio shares fall on FDA warning letter over cancer therapy claims in ad reut.rs/4rQ7Fkk
ImmunityBio shares fall on FDA warning letter over cancer therapy claims in ad
Shares of ImmunityBio fell 26% on Tuesday after the U.S. Food and Drug Administration issued a warning letter that said a television advertisement and podcast promoting the company's cancer therapy were false or misleading and violated federal law.
reut.rs
March 24, 2026 at 7:40 PM
ImmunityBio shares fall on FDA warning letter over cancer therapy claims in ad reut.rs/4rQ7Fkk
FDA Flags Misleading Claims on Cancer Drug Made by Billionaire Owner of ImmunityBio www.medpagetoday.com/publichealth...
FDA Flags Misleading Claims on Cancer Drug Made by Billionaire Owner of ImmunityBio
Patrick Soon-Shiong recently said Anktiva may be able to cure or prevent other cancers
www.medpagetoday.com
March 24, 2026 at 11:09 PM
FDA Flags Misleading Claims on Cancer Drug Made by Billionaire Owner of ImmunityBio www.medpagetoday.com/publichealth...
Hoffnungsvoller Therapieansatz: Derzeit wird in den USA für eine Studie rekrutiert zur Behandlung von Long Covid mit ANKTIVA (Medikament, das insbesondere Killerzellen aktiviert).
immunitybio.com/immunitybio-...
immunitybio.com/immunitybio-...
ImmunityBio Announces Phase 2 Study of ANKTIVA® in Patients with Long COVID - ImmunityBio
immunitybio.com
September 7, 2025 at 4:23 PM
Hoffnungsvoller Therapieansatz: Derzeit wird in den USA für eine Studie rekrutiert zur Behandlung von Long Covid mit ANKTIVA (Medikament, das insbesondere Killerzellen aktiviert).
immunitybio.com/immunitybio-...
immunitybio.com/immunitybio-...
das tut mir schrecklich leid zu hören. Du bist immer so nett und hast schon so vielen geholfen. Ich verstehe aus deinen Post, dass die Situation aussichtslos ist. Aber dir würde nicht evtl das helfen, was ImmunityBio gerade in den ganzen Studien mit Anktiva macht?
February 23, 2026 at 12:21 PM
das tut mir schrecklich leid zu hören. Du bist immer so nett und hast schon so vielen geholfen. Ich verstehe aus deinen Post, dass die Situation aussichtslos ist. Aber dir würde nicht evtl das helfen, was ImmunityBio gerade in den ganzen Studien mit Anktiva macht?
ANKTIVA aktiviert sogenannte „Killerzellen“, deren Funktion bei vielen ME/CFS Erkrankten eingeschränkt ist.
immunitybio.com/immunitybio-...
immunitybio.com/immunitybio-...
ImmunityBio Announces Phase 2 Study of ANKTIVA® in Patients with Long COVID - ImmunityBio
immunitybio.com
September 7, 2025 at 2:36 PM
ANKTIVA aktiviert sogenannte „Killerzellen“, deren Funktion bei vielen ME/CFS Erkrankten eingeschränkt ist.
immunitybio.com/immunitybio-...
immunitybio.com/immunitybio-...
Solving the Global BCG Shortage with ImmunityBio’s Supercharged BCG - Pat Soon-Shiong
oncodaily.com/voices/pat-s...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #BCG #ImmunityBio
oncodaily.com/voices/pat-s...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #BCG #ImmunityBio
Pat Soon-Shiong: Solving the Global BCG Shortage with ImmunityBio’s Supercharged BCG - OncoDaily
Pat Soon-Shiong: Solving the Global BCG Shortage with ImmunityBio’s Supercharged BCG / BCG, cancer, ImmunityBio, OncoDaily, Oncology, Pat Soon-Shiong, UroToday
oncodaily.com
October 31, 2025 at 1:40 PM
Solving the Global BCG Shortage with ImmunityBio’s Supercharged BCG - Pat Soon-Shiong
oncodaily.com/voices/pat-s...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #BCG #ImmunityBio
oncodaily.com/voices/pat-s...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #BCG #ImmunityBio
But it looks like the billionaire scientist’s support is ultimately self-serving. As Kennedy’s confirmation advances, ImmunityBio, Soon-Shiong’s biotech firm, has three pending drug applications in front of the Food and Drug Administration.
newrepublic.com/post/191212/...
newrepublic.com/post/191212/...
RFK Jr.’s Most Surprising Ally is the LA Times Owner. Here’s Why.
Patrick Soon-Shiong has been extra vocal in his support for Robert F. Kennedy Jr.
newrepublic.com
February 6, 2025 at 12:19 AM
But it looks like the billionaire scientist’s support is ultimately self-serving. As Kennedy’s confirmation advances, ImmunityBio, Soon-Shiong’s biotech firm, has three pending drug applications in front of the Food and Drug Administration.
newrepublic.com/post/191212/...
newrepublic.com/post/191212/...
'Friday, ImmunityBio said the two complete responses are ongoing after seven and 15 months. The patients received four cycles of CD19 CAR-NK plus rituximab, with no further treatment thereafter. Current standards of care failed both patients, who had extensive disease at baseline.'
ImmunityBio touts 15-month complete response in off-the-shelf CAR-NK trial
ImmunityBio has
www.fiercebiotech.com
January 18, 2026 at 7:37 AM
'Friday, ImmunityBio said the two complete responses are ongoing after seven and 15 months. The patients received four cycles of CD19 CAR-NK plus rituximab, with no further treatment thereafter. Current standards of care failed both patients, who had extensive disease at baseline.'
'ImmunityBio Announces Phase 2 Study of ANKTIVA in Patients with Long COVID'
'Long COVID remains a significant public health challenge with no currently available established treatments'
ir.immunitybio.com/news-release...
'Long COVID remains a significant public health challenge with no currently available established treatments'
ir.immunitybio.com/news-release...
ir.immunitybio.com
August 19, 2025 at 5:00 PM
'ImmunityBio Announces Phase 2 Study of ANKTIVA in Patients with Long COVID'
'Long COVID remains a significant public health challenge with no currently available established treatments'
ir.immunitybio.com/news-release...
'Long COVID remains a significant public health challenge with no currently available established treatments'
ir.immunitybio.com/news-release...
Weekly #regenerative reads: Gattaca stack, animal sacks, custom iPS cells, ImmunityBio FDA warning, mouse cloning limit ipscell.com/2026/03/week... #stemcells #stemcell
Weekly reads: Gattaca stack, animal sacks, custom iPS cells, ImmunityBio FDA warning, mouse cloning limit - The Niche
Professor discusses regenerative news: Gattaca stack, animal sacks, custom iPS cells, ImmunityBio FDA warning, mouse cloning limit
ipscell.com
March 29, 2026 at 4:18 PM
Weekly #regenerative reads: Gattaca stack, animal sacks, custom iPS cells, ImmunityBio FDA warning, mouse cloning limit ipscell.com/2026/03/week... #stemcells #stemcell
@altfda.altgov.info FDA objects to Patrick Soon-Shiong's podcast “Is the FDA BLOCKING Life Saving Cancer Treatments?”
So FDA claims complaining about its capricious clown show, formerly known as CBER approval, constitutes false and misleading advertising?
ROTFLMAO
So FDA claims complaining about its capricious clown show, formerly known as CBER approval, constitutes false and misleading advertising?
ROTFLMAO
ImmunityBio, Inc. - 725468 - 03/13/2026
False & Misleading Claims/Misbranded
www.fda.gov
March 24, 2026 at 1:46 PM
@altfda.altgov.info FDA objects to Patrick Soon-Shiong's podcast “Is the FDA BLOCKING Life Saving Cancer Treatments?”
So FDA claims complaining about its capricious clown show, formerly known as CBER approval, constitutes false and misleading advertising?
ROTFLMAO
So FDA claims complaining about its capricious clown show, formerly known as CBER approval, constitutes false and misleading advertising?
ROTFLMAO
It’s a great pity that the boss is an unpleasant person to attempt to do business with, because it looks as though ImmunityBio may really be onto something.
'CD19 CAR-NK is a targeted high-affinity natural killer cell therapy – an off-the-shelf, allogeneic NK cell line engineered to express a CD19-specific chimeric antigen receptor (CAR) and a high-affinity CD16 (FcγRIIIa 158V) receptor.'
www.businesswire.com/news/home/20...
www.businesswire.com/news/home/20...
www.businesswire.com
January 18, 2026 at 8:45 AM
It’s a great pity that the boss is an unpleasant person to attempt to do business with, because it looks as though ImmunityBio may really be onto something.
ImmunityBio, Inc. has launched a Phase 2 trial of ANKTIVA, a first-in-class IL-15 agonist, to evaluate safety and immune effects in patients with long COVID, an ongoing condition affecting 1 in 5 US adults. #IDsky #MEDsky
Read more: www.contagionlive.com/view/immunit...
Read more: www.contagionlive.com/view/immunit...
ImmunityBio Launches Phase 2 Trial of ANKTIVA for Long COVID
First-in-class IL-15 agonist aims to address persistent post-COVID symptoms by enhancing immune clearance and restoring T cell memory.
www.contagionlive.com
August 21, 2025 at 1:20 PM
ImmunityBio, Inc. has launched a Phase 2 trial of ANKTIVA, a first-in-class IL-15 agonist, to evaluate safety and immune effects in patients with long COVID, an ongoing condition affecting 1 in 5 US adults. #IDsky #MEDsky
Read more: www.contagionlive.com/view/immunit...
Read more: www.contagionlive.com/view/immunit...
FDA slams Soon-Shiong and ImmunityBio for making ‘false and misleading’ claims about a drug.. statnews.com/pharmalot/20... #pharma #FDA #misleading #ImmunityBio #cancer #soonshiong
FDA slams Soon-Shiong and ImmunityBio for making 'false and misleading' claims about a drug
Patrick Soon-Shiong, a controversial figure in the biotech industry, was accused by the FDA of making false and misleading claims about a cancer treatment.
statnews.com
March 24, 2026 at 4:13 PM
FDA slams Soon-Shiong and ImmunityBio for making ‘false and misleading’ claims about a drug.. statnews.com/pharmalot/20... #pharma #FDA #misleading #ImmunityBio #cancer #soonshiong
A new #PostCOVID / #LongCOVID single-arm study by ImmunityBio of Anktiva, an interleukin-15 receptor agonist which is used to treat bladder cancer.
20 patients will be enrolled at UCSF in San Francisco, with the study planned to start this month.
clinicaltrials.gov/study/NCT071...
20 patients will be enrolled at UCSF in San Francisco, with the study planned to start this month.
clinicaltrials.gov/study/NCT071...
ClinicalTrials.gov
clinicaltrials.gov
August 6, 2025 at 2:45 PM
A new #PostCOVID / #LongCOVID single-arm study by ImmunityBio of Anktiva, an interleukin-15 receptor agonist which is used to treat bladder cancer.
20 patients will be enrolled at UCSF in San Francisco, with the study planned to start this month.
clinicaltrials.gov/study/NCT071...
20 patients will be enrolled at UCSF in San Francisco, with the study planned to start this month.
clinicaltrials.gov/study/NCT071...
Stocks making the biggest moves premarket: PNC, ImmunityBio, Coupang & more
Stocks making the biggest moves premarket: PNC, ImmunityBio, Coupang & more
These are the stocks posting the largest moves in premarket trading.
cnb.cx
January 16, 2026 at 12:54 PM
Stocks making the biggest moves premarket: PNC, ImmunityBio, Coupang & more
(Gift Article) DESPICABLE: Soon-Shiong’s Drug Deception
As the FDA cracks down on the Los Angeles Times the newspaper’s studio arm has been entangled in promoting them—raising ethical alarms among staff.
www.bloomberg.com/news/article...
As the FDA cracks down on the Los Angeles Times the newspaper’s studio arm has been entangled in promoting them—raising ethical alarms among staff.
www.bloomberg.com/news/article...
ImmunityBio Plunges After Getting FDA Warning on Cancer Drug
ImmunityBio Inc.’s shares plunged after the biotechnology company and its billionaire executive chairman, Patrick Soon-Shiong, were hit with a Food and Drug Administration warning letter for false and...
www.bloomberg.com
March 29, 2026 at 12:39 AM
(Gift Article) DESPICABLE: Soon-Shiong’s Drug Deception
As the FDA cracks down on the Los Angeles Times the newspaper’s studio arm has been entangled in promoting them—raising ethical alarms among staff.
www.bloomberg.com/news/article...
As the FDA cracks down on the Los Angeles Times the newspaper’s studio arm has been entangled in promoting them—raising ethical alarms among staff.
www.bloomberg.com/news/article...
Zur Info, ImmunityBio ist das Unternehmen, das in den letzten Wochen auch an der Börse richtig durchgestartet ist (400% steigerung). Anktiva ist der Wirkstoff, bzw sind das NK Zellen die speziell trainiert werden (eine neue Art Immuntherapie).
February 23, 2026 at 12:36 PM
Zur Info, ImmunityBio ist das Unternehmen, das in den letzten Wochen auch an der Börse richtig durchgestartet ist (400% steigerung). Anktiva ist der Wirkstoff, bzw sind das NK Zellen die speziell trainiert werden (eine neue Art Immuntherapie).
FDA issues warning letter to ImmunityBio over misleading claims about cancer drug
https://cancerletter.com/cancer-policy/20260327_8a/
https://cancerletter.com/cancer-policy/20260327_8a/
FDA issues warning letter to ImmunityBio over misleading claims about cancer drug - The Cancer Letter
ImmunityBio and its owner and executive chairman Patrick Soon-Shiong received a warning letter from FDA for making false and misleading claims about a cancer treatment in television ads and on a podcast. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in with IP-login or register for […]
cancerletter.com
March 28, 2026 at 10:00 AM
FDA issues warning letter to ImmunityBio over misleading claims about cancer drug
https://cancerletter.com/cancer-policy/20260327_8a/
https://cancerletter.com/cancer-policy/20260327_8a/
Culver City researchers will enroll 40 patients with long COVID in a Phase 2 trial of ANKTIVA, an IL-15 agonist that boosts NK and T cells.
The study will test safety and immune effects, aiming to offer a first treatment.
ir.immunitybio.com/news-release...
The study will test safety and immune effects, aiming to offer a first treatment.
ir.immunitybio.com/news-release...
ImmunityBio Announces Phase 2 Study of ANKTIVA® in Patients with Long COVID | ImmunityBio, Inc.
Approximately one in five American adults who had COVID-19 still experience symptoms of long COVID, a serious illness that can result in chronic conditions and disability 1.2 Long COVID remains a sign...
ir.immunitybio.com
August 19, 2025 at 1:14 PM
Culver City researchers will enroll 40 patients with long COVID in a Phase 2 trial of ANKTIVA, an IL-15 agonist that boosts NK and T cells.
The study will test safety and immune effects, aiming to offer a first treatment.
ir.immunitybio.com/news-release...
The study will test safety and immune effects, aiming to offer a first treatment.
ir.immunitybio.com/news-release...
das klingt furchtbar. Aber auch nach dem, was in den Studien mit ImmunityBio / Anktiva behandelt wird. Zugelassen ist es in der EU bis jetzt nur für Blasenkrebs. In den USA arbeiten sie an der Zulassung für andere Krebsarten, was in Saudi-Arabien gerade passiert ist. Wäre Info auch auf Englisch ok?
February 23, 2026 at 12:34 PM
das klingt furchtbar. Aber auch nach dem, was in den Studien mit ImmunityBio / Anktiva behandelt wird. Zugelassen ist es in der EU bis jetzt nur für Blasenkrebs. In den USA arbeiten sie an der Zulassung für andere Krebsarten, was in Saudi-Arabien gerade passiert ist. Wäre Info auch auf Englisch ok?